UBS
http://www.ubs.com/UBS provides a range of financial services, including advisory services, underwriting, financing, market making, asset management, brokerage and retail banking on a global level. The Company consists of four divisions: Wealth Management, Asset Management, Investment Banking & Security and Swiss Retail & Corporate Banking. Wealth Management offers high net worth customers advice and investment services, Asset Management offers management solutions for most types of asset class to a range of clients, Investment Banking & Security provides securities, products and research in various areas equities and Swiss Retail & Corporate Banking offers banking and securities services for Swiss clients.
-
UBS Maintains a 'Neutral' on Alkermes (ALKS); Scaling Up and Diversifying
-
UPDATE - UBS Downgrades Alkermes (ALKS) to Neutral; Bydureon’s Delay Puts Overhang on Shares
-
UBS Downgrades Alkermes (ALKS) to Neutral
-
Wave of Downgrades Hits Amylin, Alkermes, Eli Lilly (AMLN, ALKS, LLY)
-
Notable Analyst Rating Changes 10/14: F, VOD, PHM, MGM Upgraded; APOL, ALKS, NIHD, RAX Downgraded
-
UBS Initiates Coverage on Alkermes (ALKS) with a Buy; Finally Ready to Breakout?
-
UBS Starts Alkermes (ALKS), Par Pharma (PRX) at Buy, Salix Pharma (SLXP) at Neutral
-
Notable Analyst Rating Changes 07/14: AKS, ADTN, CRM, MOT Upgraded; LXK, PX, WTNY, ADCT Downgraded
-
Notable Analyst Rating Changes 11/17: XOM, PALM, ALKS, ITW, SINA Upgraded; SPWRA, PARD, PSUN, JOYG Downgraded
-
Morning Movers 3/31: AMLN, TBSI, FUQI, TXT, STSI Higher; TLCV, ACOR, ALTH, OXM, HIG Lower
